Mechanistically, NSD2 directly governed the transcriptional activation of Ern1 through H3K36me2, thus activating the ERN1–JNK axis to exacerbate intestinal barrier impairment and subsequently promote NASH progression. Here, NSD2 is linked to metabolic dysfunction-associated steatohepatitis.